# Teladoc's disappointing earnings are causing a knee-jerk sell-off across healthcare stocks as investors flee the sector. But Novo Nordisk and Eli Lilly operate in the booming weight-loss drug market, which is completely disconnected from telehealth strugg

_AI-generated trading idea · BULLISH · LLY, NVO_

> Canonical page: https://commonquant.ai/research/for-you/teladoc-s-disappointing-earnings-are-causing-a-knee-jerk-sel--20590961-6e03-48fa-9883-6c03576b476c

Teladoc's disappointing earnings are causing a knee-jerk sell-off across healthcare stocks as investors flee the sector. But Novo Nordisk and Eli Lilly operate in the booming weight-loss drug market, which is completely disconnected from telehealth struggles. With both companies heading into their own earnings reports, this panic-driven dip is a chance to buy these high-demand stocks at a discount before their results likely remind the market of their fundamental strength.

## Idea

Teladoc's disappointing earnings are causing a knee-jerk sell-off across healthcare stocks as investors flee the sector. But Novo Nordisk and Eli Lilly operate in the booming weight-loss drug market, which is completely disconnected from telehealth struggles. With both companies heading into their own earnings reports, this panic-driven dip is a chance to buy these high-demand stocks at a discount before their results likely remind the market of their fundamental strength.

## Advanced Analysis

### Verdict: Wait — the dip-buying thesis is alive but the trigger hasn't fired and may be too strict to ever fire

The idea's core thesis — that a Teladoc-driven healthcare panic is mispricing GLP-1 leaders — has real fundamental legs for Eli Lilly, whose 44.7% revenue growth and 77.8% ROE place it in the top decile of healthcare peers. But the setup demands simultaneous RSI below 35, Stochastic %K below 30, and a support touch, and across 1,718 evaluated bars over two windows the rules have never triggered once. That makes this a disciplined watch-list exercise, not a live trade: the strategy is designed to catch exhaustion, and today neither ticker has washed out enough — NVO's Stochastic %K sits at 46.7 (16.7 points above the sub-30 gate) and LLY's at 37.9 (7.9 points away). The deeper problem is NVO itself: 6.4% revenue growth, a current ratio of 0.80, and a 74.6% historical max drawdown undercut the "booming demand" framing and make it the basket's structural drag. No robust parameter setup was established through sensitivity testing, so the original strict thresholds stand.

\*\*Conviction Breakdown\*\*

\| Dimension \| Score \| Rationale \|
\|---\|---\|---\|
\| Thesis Support \| 55 \| The telehealth-contagion disconnect is plausible for LLY (44.7% revenue growth, 77.8% ROE) but weak for NVO (6.4% growth, only 35th percentile among peers). \|
\| Trade Readiness \| 25 \| Zero triggers across 1,718 bars; Stochastic %K is 7.9–16.7 points from the sub-30 gate on both tickers, and no relaxed setup was established. \|
\| Risk Quality \| 55 \| The 2.5% stop and 2:1 reward-to-risk are disciplined, but NVO's 49.7% annualized volatility and 74.6% max drawdown make the basket vulnerable to gap-throughs. \|
\| Trigger Proximity \| 30 \| NVO has RSI (31.4) and support ($47.00) in place but needs a 16.7-point Stochastic drop; LLY needs both a deeper RSI breach and a $97 pullback to $1,052 support. \|
\| Fundamentals Trend \| 60 \| LLY's growth and margins are accelerating; NVO's margins are compressing (gross margin down to 81.0% from 84.7%) and its current ratio of 0.80 signals liquidity pressure. \|

#### Conviction score breakdown

Composite score computed by the server from the applicable evidence-tier dimensions.

| Measure | Value |
| --- | ---: |
| Thesis support | 55/100 |
| Trade readiness | 25/100 |
| Risk quality | 55/100 |
| Trigger proximity | 30/100 |
| Fundamentals trend | 60/100 |
| Score | 45/100 |
| Composite Score | 45/100 |
| Evidence Tier | rules\_not\_triggered |

#### Decision scenarios

Bull, base, and bear cases synthesized from the cited evidence tier. Likelihoods are rounded evidence-weighted judgments, not statistically calibrated forecasts.

| Measure | Value |
| --- | ---: |
| Evidence Tier | rules\_not\_triggered |

### Trade now

Neither ticker has triggered an entry yet, so the instruction today is to wait — but the waiting is active. The strategy requires four conditions to fire simultaneously: RSI (14) below 35, Stochastic %K crossing above %D while %K itself is still below 30, price touching the nearest support level, and then closing above the prior close. For Eli Lilly, RSI sits at 35.0 — effectively at the threshold — but Stochastic %K is at 37.9, still well above the sub-30 zone needed for the crossover condition. Price at $1,148.8 is also sitting right at nearest resistance ($1,149.1), not the $1,052.2 support the entry requires. Novo Nordisk is further along on the oversold axis: RSI is already at 31.4 (below the 35 gate) and price at $47.08 is essentially on top of its $47.00 nearest support. However, Stochastic %K at 46.7 is nowhere near the sub-30 band the strategy demands before it will recognize a momentum turn.

The invalidation framework is tight by design. Once entered, a fixed stop caps losses at roughly 2.5% and take-profit targets approximately 4.9%, giving an effective reward-to-risk near 2:1. The strategy also layers in a Fibonacci 78.6% retracement stop-loss and a new-low invalidation. Because no robust parameter setup was established through sensitivity testing (the evaluation exceeded its time budget), there is no adjusted or relaxed threshold set to fall back on — the original, stricter rules stand.

"Wait" means something concrete here: set alerts on Stochastic %K dropping below 30 for both tickers, since that is the condition furthest from being met on NVO (16.7 points away) and significantly off on LLY (7.9 points away). For LLY, also watch for a roughly $97 pullback from current price to the $1,052 support level. NVO is the closer candidate — RSI and support are already in place — but it needs a deeper Stochastic wash-out before the crossover signal can even be evaluated.

#### LLY price and trigger map

Uses the idea timeframe and keeps price levels on the price axis.

| Measure | Value |
| --- | ---: |
| Ticker | LLY |
| Timeframe | 1d |

#### NVO price and trigger map

Uses the idea timeframe and keeps price levels on the price axis.

| Measure | Value |
| --- | ---: |
| Ticker | NVO |
| Timeframe | 1d |

### Why the GLP-1 Demand Story Still Has Teeth

The central thesis — that a telehealth-driven sell-off is dragging down fundamentally unrelated weight-loss stocks — rests on a…

#### NVO Revenue

Revenue trend from CommonQuant fundamentals/XBRL data; +186.4% from first to latest point.

| Measure | Value |
| --- | ---: |
| 2015-12-31 | $107927000000 |
| 2016-12-31 | $111780000000 |
| 2017-12-31 | $111696000000 |
| 2018-12-31 | $111831000000 |
| 2019-12-31 | $122021000000 |
| 2020-12-31 | $126946000000 |
| 2021-12-31 | $140800000000 |
| 2022-12-31 | $176954000000 |
| 2023-12-31 | $232261000000 |
| 2024-12-31 | $290403000000 |
| 2025-12-31 | $309064000000 |
| Latest Value | $309064000000 |
| Change Pct | $186.36393117570208 |
| Ticker | NVO |
| Timeframe | reported periods |

#### LLY Return on equity

Return on equity trend from CommonQuant fundamentals/XBRL data; +124.6% from first to latest point.

| Measure | Value |
| --- | ---: |
| 2008-12-31 | \-0.3075084969648396% |
| 2009-06-30 | \0.13533878504672897% |
| 2009-09-30 | \0.3446138313982837% |
| 2009-09-30 | \0.09508329126703684% |
| 2009-12-31 | \0.45445287812457347% |
| 2010-03-31 | \0.1192949924968697% |
| 2010-06-30 | \0.13178900471896282% |
| 2010-09-30 | \0.10502599653379548% |
| 2010-12-31 | \0.4081624437412945% |
| 2011-03-31 | \0.07577758321252745% |
| Latest Value | \0.07577758321252745% |
| Change Pct | \124.642435562095% |
| Ticker | LLY |
| Timeframe | reported periods |

#### LLY sector percentile check

Ranks LLY against 943 companies in its sector using CommonQuant fundamentals.

| Measure | Value |
| --- | ---: |
| Return on equity | \90.2439024390244th percentile |
| Gross margin | \79.08045977011494th percentile |
| Revenue growth (YoY) | \59.65189873417721th percentile |
| Ticker | LLY |
| Sector | Health Care |
| Peer Count | 943 |

### Scores

- **Conviction score breakdown:** 45
- **Thesis support:** 55
- **Trade readiness:** 25
- **Risk quality:** 55
- **Trigger proximity:** 30
- **Fundamentals trend:** 60

### Watch items

- **LLY — RSI (14)**
- **LLY — Stochastic (14) %K**
- **LLY — Price vs nearest support**
- **NVO — RSI (14)**
- **NVO — Stochastic (14) %K**
- **NVO — Price vs nearest support**
- **NVO — Annualized return (730-day)**
- **LLY — RSI (14) below 35**
- **LLY — Stochastic (14) crossed above Stochastic (14)**
- **LLY — Stochastic (14) below 30**
- **LLY — Price above Price**

## Key details

- Symbols: LLY, NVO
- Timeframes: 1d
- Tags: \#canonical-demand, \#cluster-version:1, \#direction:bullish, \#entity-kind:instrument, \#entity:LLY, \#entity:NVO, \#horizon:unspecified, \#intent:research, \#symbol:LLY, \#symbol:NVO

## Community

- Upvotes: 19
- Views: 220
- Copies: 0
- Cosigns: 0

## News sources

- [Teladoc (TDOC) Stock Plummets on Disappointing Q2 Earnings Results](https://finance.yahoo.com/healthcare/articles/teladoc-tdoc-stock-plummets-disappointing-202603471.html) — Yahoo Finance
- [Novo Nordisk vs Eli Lilly: The Better Buy Before Earnings](https://finance.yahoo.com/healthcare/articles/novo-nordisk-vs-eli-lilly-173012209.html) — Yahoo Finance

## Discussion (5)

**@solid\_node21** · 1 upvotes

Sector rotation out of healthcare into tech has been the pattern for three weeks running. The Teladoc print is just an excuse for flows that were already heading for the door.

**@smooth\_maverick4** · 1 upvotes

Calling a 1-day dip in mega-caps a 'panic' is a stretch. These things are priced near perfection already, and the crowd piling into GLP-1 names is the most crowded trade of the year.

**@liquid\_viper2** · 1 upvotes

What's the actual margin of safety here though? LLY trades at something like 60x forward earnings, you're not exactly buying a discount just because it's down 2% on a random Teladoc spill.

## Related

- [LLY trade ideas](https://commonquant.ai/stocks/lly)
- [NVO trade ideas](https://commonquant.ai/stocks/nvo)
- [Latest market news](https://commonquant.ai/news)

## About CommonQuant Research

Ideas and Advanced Analysis are generated with fresh, LLM-selected news headlines and grounded in SEC XBRL fundamentals and peer percentiles. Strategies built from these ideas are automatically backtested (12-month and 5-year, walk-forward tuned) and stress-tested before they can go live, then monitored against the news hourly while they run.